Cancer has long been understood as a disease of the genome, driven by mutations that rewire the instructions encoded in DNA. Over the past three decades, however, a parallel truth has crystallized: cancer is equally a disease of the epigenome, the layer of chemical marks that sits atop the genetic code and determines which genes are silenced and which are expressed. Among these marks, DNA methylation—the addition of a methyl group to cytosine bases, typically at CpG dinucleotides—has emerged as one of the most consistently disrupted features of tumor cells. A new review published in Cellular and Molecular Life Sciences by Negar Sadeghi, Euan J. Rodger and Aniruddha Chatterjee of the University of Otago argues that the field now stands at a decisive turning point, one where CRISPR-based DNA methylation editing could finally convert decades of correlative observation into mechanistic understanding and, ultimately, precision therapy.
The scale of methylation disruption in cancer is staggering. Tumor genomes characteristically display widespread global hypomethylation, in which vast stretches of normally methylated DNA lose their marks, accompanied by focal hypermethylation concentrated at key regulatory regions, particularly the CpG-rich promoters of tumor suppressor genes. The result is an extensive rewiring of gene regulatory networks: genes that restrain cell division are switched off, repetitive elements that are normally locked down become active, and the carefully orchestrated patterns that define cell identity dissolve into chaos. These alterations are so consistent that methylation signatures now underpin diagnostic and prognostic assays used in clinics worldwide, helping pathologists classify tumors, predict patient outcomes, and even trace the tissue of origin of metastatic cancers.
Yet a profound gap separates correlation from causation. The overwhelming majority of cancer-associated methylation changes have never been proven to drive tumor behavior; they may instead be passive consequences of the transformed state. Distinguishing driver marks from passenger marks using observational methylome profiling alone has proved remarkably difficult, because the epigenome is dynamic and context-dependent. This ambiguity has real consequences for drug development. Conventional hypomethylating agents, such as nucleoside analogs that trap and deplete methyltransferase enzymes, can partially reverse cancer-associated methylation alterations and have demonstrated clinical efficacy in selected hematological malignancies. But these drugs act genome-wide, with no capacity to target a specific promoter or enhancer. Their blunt mechanism limits both mechanistic insight—since any observed effect could stem from thousands of altered loci—and therapeutic precision, since desirable and undesirable demethylation occur simultaneously across the genome.
CRISPR-based epigenome editing offers a fundamentally different approach. Rather than cutting DNA, these systems repurpose catalytically inactive Cas proteins, most famously dCas9, as programmable delivery vehicles. Guided to a chosen genomic address by a complementary guide RNA, dCas9 can be fused to methylation ‘writers’—enzymes such as DNMT3A and DNMT3L that install methyl marks—or methylation ‘erasers’, including TET1 catalytic domains and engineered demethylases that oxidize and remove them. Because the underlying DNA sequence is left untouched, the editing is, in principle, reversible, mirroring the reversible nature of the epigenetic alterations themselves. The result is a technology capable of quantitatively tuning methylation at individual promoters, enhancers, and CpG shores—transition zones flanking CpG islands that are frequent sites of cancer-associated methylation gain.
The experimental power of this approach lies in its precision. A single tumor suppressor promoter can be hypermethylated in a controlled setting to test whether silencing of that gene is sufficient to confer growth advantages, or demethylated to ask whether restoring its expression suppresses malignant behavior. Similar logic applies to enhancers, whose methylation status can govern the activity of oncogenes and immune-modulatory genes alike. By editing specific loci, researchers can interrogate mechanisms of chemoresistance, asking whether methylation changes at particular drug-response genes cause treatment failure or merely accompany it. They can also probe immune modulation, since methylation patterns influence the expression of antigen-presenting molecules and immune checkpoint pathways that determine whether tumors are recognized by the immune system. In this way, methylation editing transforms the epigenome from a readout of tumor state into an experimentally addressable variable.
The review also highlights the modular nature of modern CRISPR recruitment platforms, which extend the technology well beyond simple enzyme fusions. Systems such as SunTag, MS2-based scaffolds, and related multiplexing strategies allow multiple effector domains to be recruited to a single target site, amplifying the magnitude of methylation change or combining writers and erasers with transcriptional activators and repressors. Such platforms enable graduated, quantitative manipulation of methylation levels rather than all-or-nothing switching, which is critical because the relationship between methylation density and gene expression is often dose-dependent. Combined with single-cell and multi-omics readouts, these tools allow researchers to observe how a targeted methylation edit propagates through chromatin state, transcription, and ultimately cellular phenotype in diverse cancer models, from cell lines to patient-derived organoids.
None of this progress comes without caveats, and the authors are candid about the obstacles that stand between bench and bedside. Off-target activity remains a central concern: both the DNA-binding specificity of guide RNAs and the promiscuity of the tethered enzymes can produce unintended methylation changes at sites resembling the intended target, and even at sites tethered transiently by direct enzyme-to-dCas9 fusions. Because methylation changes can be heritable through cell division, a single off-target event could have lasting consequences. Context-dependency poses a further complication. The same edit can yield different outcomes depending on chromatin context, cell type, CpG density, and the developmental or disease state of the cell, complicating efforts to generalize results across models. Delivery and durability add clinical dimensions to these challenges: getting large editing constructs efficiently into tumor cells—whether in culture or in a patient—and ensuring that the methylation change persists long enough to be therapeutically meaningful remain unsolved engineering problems.
The path forward, the review argues, lies in integration. Locus-specific editing is poised to converge with comprehensive multi-omics profiling, in which methylome, transcriptome, chromatin accessibility, and three-dimensional genome architecture are measured simultaneously before and after an edit. Machine-learning-guided target selection promises to accelerate this process, mining large epigenomic datasets to prioritize the methylation changes most likely to act as drivers, and to predict how editing a given locus will ripple through regulatory networks. Rational combination therapies represent the clinical endpoint of this vision: methylation editing might, for instance, be paired with immune checkpoint inhibitors by demethylating and reactivating antigen presentation genes, or with conventional chemotherapy by erasing methylation marks that drive drug resistance. Each of these strategies depends on the causal knowledge that only targeted editing can generate.
The significance of this synthesis extends beyond the technical details. For a generation, epigenetic therapy has been constrained by an uncomfortable irony: doctors could alter the cancer epigenome, but only in a coarse, genome-wide fashion that revealed little about which alterations mattered. CRISPR-based methylation editing inverts that logic, making the epigenome writable at single-locus resolution and thereby testable in a way no previous technology allowed. If the challenges of specificity, delivery, and context can be met, the result would be a new class of therapeutics that silence oncogenes or resurrect tumor suppressors without touching a single base of DNA sequence. For now, the technology’s greatest value is as an engine of discovery—a way to finally separate the drivers from the passengers in the cancer methylome. But the trajectory is clear, and the authors’ message is that rewriting the cancer epigenome has moved from metaphor to laboratory reality, with clinical translation as the next horizon.
One reason methylation is such an attractive target for editing is its intrinsic stability. Unlike histone modifications, which turn over rapidly and often require continuous reinforcement, DNA methylation at CpG sites can be faithfully copied through cell division by maintenance methyltransferases that recognize hemimethylated DNA after replication. This means a single, well-placed edit has the potential to persist across many generations of cells, a property that is both a strength for durable therapy and a liability if the wrong loci are modified. The review’s emphasis on precision reflects this double-edged character of the methylation mark.
The choice of effector enzymes also matters greatly. DNMT3A, one of the writer domains commonly fused to dCas9, is itself a gene frequently mutated in hematological malignancies, illustrating how the machinery of methylation regulation is intimately entangled with cancer biology. On the eraser side, catalytic domains derived from the TET enzymes, which normally initiate active demethylation through oxidation of 5-methylcytosine, can be repurposed for targeted removal of marks. That these same pathways are dysregulated in tumors underscores why locus-specific manipulation is such a valuable experimental tool: it allows individual components of an altered network to be tested in isolation.
The work emerges from a research group with a sustained focus on cancer epigenomics at the University of Otago’s Department of Pathology and Molecular Medicine, and the article is published open access under a Creative Commons Attribution license, supported by New Zealand funding bodies including the Health Research Council and the Marsden Fund. Open availability is significant for a methods-oriented review, since widespread adoption of these editing approaches depends on researchers across disciplines and resource settings being able to evaluate the technical trade-offs in detail.
It is also worth noting that the review appears at a moment when epigenome editing more broadly is maturing beyond proof-of-principle demonstrations. The same dCas9 recruitment logic underlies efforts to edit histone marks, chromatin architecture, and transcriptional states, suggesting that methylation editing will ultimately function as one module within a larger toolkit for writing and rewriting the regulatory layer of the genome.
Subject of Research: CRISPR-based DNA methylation editing technologies for interrogating and potentially treating aberrant cancer epigenomes
Article Title: Rewriting the cancer epigenome: CRISPR technologies for DNA methylation editing
Article References: Sadeghi, N., Rodger, E. J., & Chatterjee, A. (2026). Rewriting the cancer epigenome: CRISPR technologies for DNA methylation editing. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06429-1
Image Credits: AI Generated
DOI: 10.1007/s00018-026-06429-1
Keywords: cancer, epigenetics, DNA methylation, CRISPR, DNA methylation editing, dCas9, epigenome editing, tumor suppressor genes, off-target effects, epigenetic therapy, gene regulation, precision medicine
Cite Scienmag News
APA MLA Chicago
Juliet Wilcox. (September 12, 2026). CRISPR Methylation Editing Rewrites the Cancer Epigenome Toward Causation. Scienmag. https://scienmag.com/crispr-methylation-editing-rewrites-the-cancer-epigenome-toward-causation/
Juliet Wilcox. “CRISPR Methylation Editing Rewrites the Cancer Epigenome Toward Causation.” Scienmag, 12 September 2026, https://scienmag.com/crispr-methylation-editing-rewrites-the-cancer-epigenome-toward-causation/. Accessed 12 September 2026.
Juliet Wilcox. “CRISPR Methylation Editing Rewrites the Cancer Epigenome Toward Causation.” Scienmag. September 12, 2026. https://scienmag.com/crispr-methylation-editing-rewrites-the-cancer-epigenome-toward-causation/
Copy citation Download RIS
Tags: advances in epigenetic research for cancer treatmentcancercausalCRISPRCRISPR-based DNA methylation editing in cancerdCas9DNA MethylationDNA methylation editingepigenetic reprogramming for cancer therapyepigenetic therapyepigeneticsepigenome and cancer developmentepigenome editingGene regulationglobal hypomethylation and focal hypermethylation in tumorsmechanisms of methylation disruption in canceroff-target effectsPrecision medicineprecision medicine through epigenome editingrewiring gene regulatory networks in cancerrole of DNA methylation in tumor suppressor gene silencingtargeted epigenetic modifications using CRISPRtumor suppressor genes
